Investors focused on the Medical space have likely heard of Genesis Healthcare (GEN), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GEN and the rest of the Medical group's stocks.
Genesis Healthcare is one of 867 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. GEN is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for GEN's full-year earnings has moved 36.11% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that GEN has returned about 9.32% since the start of the calendar year. At the same time, Medical stocks have gained an average of 2.46%. This means that Genesis Healthcare is performing better than its sector in terms of year-to-date returns.
Looking more specifically, GEN belongs to the Medical - Nursing Homes industry, which includes 5 individual stocks and currently sits at #3 in the Zacks Industry Rank. This group has gained an average of 12.13% so far this year, so GEN is slightly underperforming its industry in this area.
Investors in the Medical sector will want to keep a close eye on GEN as it attempts to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Genesis Healthcare, Inc. (GEN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research